Patients who took palbociclib also took lived longer, but not by a significant amount. Those who received the drug lived about 37.5 months, compared with 33.3 months for those in the control group.
The drug is intended for patients with hormone receptor-positive, metastatic breast cancer.
Copyright 2015 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.